Patent US5039689A successfully refreshed from Google Patents.
US5039689A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Antiparasitic 3(4-amino benzotriazo-1-yl-)1,2-cyclopentanediols
Assignee: Wellcome Foundation Ltd
•
Filing: 1989-11-08
•
Granted: 1991-08-13
•
Expires: 2009-11-08
Abstract
Abstract The present invention relates to the use of a compound of formula (I) ##STR1## wherein R represents a hydrogen atom; a C 1-4 alkyl group; a group COR 1 wherein R 1 represents amino or C 1-4 alkoxy; or a group --CH 2 R 2 wherein R 2 represents a halogen atom (e.g. chlorine or bromine), C 1-4 alkylthio, or azido, X and Y each independently represent --CH-- or --N; and Z represents --CR 3 , wherein R 3 is hydrogen or C 1-4 alkyl, or Z represents --N--; or a physiologically acceptable salt, ester or other physiologically functional derivative thereof, for the manufacture of a medicament for the treatment and/or prophylaxis of a parasitic infection in a mammal, and to certain novel compounds of formula (I), pharmaceutical compositions containing them and processes for their preparation.
Inventors
- 👤 Susan M. Daluge
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-06 00:24
CPC Classifications
C; C07; C07D; C07D239/00; C07D239/02; C07D239/24; C07D239/28; C07D239/46; C07D239/48; A; A61; A61K; A61K31/00; A61K31/33; A61K31/395; A61K31/495; A61K31/505; A61K31/519; A61K31/52; A61P; A61P33/00; A61P33/02; C07D473/00; C07D487/00; C07D487/02; C07D487/04; Y; Y02; Y02A; Y02A50/00; Y02A50/30
Claims Analysis
Total Claims: 9
Claim 1
Independent Claim
106 words
A method for the treatment of an infection caused by Pneumocystis carinii, trypanosomal bruce: gambiense or trypanosoma bruce; rhodesiense in a mammal which comprises administering to said infected mammal a therapeutically effective infection treatment amount of a compound of formula (I) ##STR15## wherein R represents hydrogen; C 1-4 alkyl; COR 1 wherein R 1 represents amino or C 1-4 alkoxy; or --CH 2 R 2 wherein R 2 represents halogen; C 1-4 alkylthio or azido; X and Y each independently represent --CH--; and Z represents --N--; or a physiologically acceptable salt, an ester formed from a carbocyclic or sulphonic acid or other physiologically functional derivative thereof.
Claim 2
Independent Claim
106 words
A method for the treatment of an infection caused by Pneumocystis carinii, trypanosomal bruce: gambiense or trypanosoma bruce; rhodesiense in a mammal which comprises administering to said infected mammal a therapeutically effective infection treatment amount of a compound of formula (I) ##STR15## wherein R represents hydrogen; C 1-4 alkyl; COR 1 wherein R 1 represents amino or C 1-4 alkoxy; or --CH 2 R 2 wherein R 2 represents halogen; C 1-4 alkylthio or azido; X and Y each independently represent --CH--; and Z represents --N--; or a physiologically acceptable salt, an ester formed from a carbocyclic or sulphonic acid or other physiologically functional derivative thereof.
Claim 3
Dependent Claim
20 words
A method according to claim 1 wherein in the compound of formula (I) R is hydrogen or --CONH 2 .
Claim 4
Dependent Claim
29 words
A method according to claim 1 wherein the compound of formula (I) has the configuration (IA) ##STR16## wherein R, X, Y and Z are as defined in claim 1.
Claim 5
Dependent Claim
15 words
A method according to claim 1 wherein the parasitic infection is due to Pneumocystis carinii.
Claim 6
Dependent Claim
14 words
A method according to claim 1 wherein the parasitic infection is a trypanosomal infection.
Claim 7
Dependent Claim
15 words
A method according to claim 4 or claim 5 wherein the mammal is a human.
Claim 8
Dependent Claim
20 words
A compound of formula (I) wherein X, Y and Z are as defined in claim 1 and R is hydrogen.
Claim 9
Dependent Claim
33 words
A pharmaceutical formulation comprising a compound of formula (I) as defined in claim 7, or a physiologically acceptable salt, ester or other physiologically functional derivative thereof together with a pharmaceutically acceptable carrier therefor.
References Cited (Backward Citations)
US3004896A
Cited
FR1198995A
Cited
US3808334A
Cited
US4086242A
Cited
US4038403A
Cited
US4755215A
Cited
US4859677A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1994-08-12 | 1995-02-11 | 1995-08-13 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1998-08-12 | 1999-02-11 | 1999-08-13 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2002-08-12 | 2003-02-11 | 2003-08-13 | $7700.00 | Window Closed / Lapsed |